Preview

Современная ревматология

Расширенный поиск

Напроксен: универсальный анальгет и к с минимальным риском кардиоваскулярных осложнений

https://doi.org/10.14412/1996-7012-2016-2-70-77

Полный текст:

Аннотация

Нестероидные противовоспалительные препараты (НПВП) – основной инструмент, используемый в реальной клинической практике для купирования острой боли и контроля основных симптомов при хронических заболеваниях суставов и позвоночника. Они действенны, доступны и удобны в применении, однако могут вызывать нежелательные реакции (НР), которые требуют тщательного контроля и эффективной профилактики. Современная концепция безопасного использования НПВП направлена на максимальное снижение риска осложнений со стороны как желудочно-кишечного тракта (ЖКТ), так и сердечно-сосудистой системы. По данным клинических испытаний и популяционных исследований, среди всех НПВП (кроме аспирина) наименьший риск кардиоваскулярных катастроф отмечен для напроксена. Этот препарат, относящийся к «традиционным» (неселективным) НПВП (н-НПВП), широко используется в клинической практике более 40 лет и завоевал доверие врачей всего мира в качестве надежного анальгетика и противовоспалительного средства. Терапевтический потенциал напроксена доказан при самых разных заболеваниях и патологических состояниях – от острых травм до болезни Бехтерева. При использовании напроксена, как и других н-НПВП, нужно учитывать возможность развития НР со стороны ЖКТ. Однако этот риск может быть существенно снижен при назначении ингибиторов протонной помпы, таких как эзомепразол. В настоящем обзоре приведены основные исследования, в которых изучались эффективность и безопасность напроксена.

Об авторе

А. Е. Каратеев
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522, Москва, Каширское шоссе, 34А
Россия


Литература

1. Яхно НН, Кукушкин МЛ, редакторы. Боль: практическое руководство для врачей. Москва: Издательство РАМН; 2012. 512 c. [Yakhno NN, Kukushkin ML, editors. Bol' (prakticheskoe rukovodstvo dlya vrachei) [Pain (practical guide for physicians)]. Moscow: Izdatel'stvo RAMN; 2012. 512 p.]

2. Насонов ЕЛ. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой. Клиническая фармакология и терапия. 2003;12(1):64-9. [Nasonov EL. Analgesic therapy in rheumatology: a journey between Scylla and Charybdis. Klinicheskaya Farmakologiya i Terapiya. 2003;12(1):64-9. (In Russ.)].

3. Lee YC. Effect and treatment of chronic pain in inflammatory arthritis. Curr Rheumatol Rep. 2013 Jan;15(1):300. doi: 10.1007/s11926-012-0300-4.

4. van de Laar M, Pergolizzi J, Mellinghoff H, et al. Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs. Open Rheumatol J. 2012;6:320-30. doi: 10.2174/1874312901206010320. Epub 2012 Dec 13.

5. Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-24. [Karateev AE, Nasonov EL, Yakhno NN et al. Clinical guidelines «Rational use of nonsteroidal antiinflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(1):4- 24. (In Russ.)]. DOI: http://dx.doi.org/10. 14412/1996-7012-2015-1-4-23

6. Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19;13:55. doi: 10.1186/s12916-015-0285-8.

7. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-47.

8. Каратеев АЕ, Попкова ТВ, Новикова ДС и др. Оценка риска желудочно-кишечных и сердечно-сосудистых осложнений, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ: предварительные данные эпидемиологического исследования КОРОНА-2. Научно-практическая ревматология. 2014;52(6):600–6. [Karateev AE, Popkova TV, Novikova DS, et al. Assessment of risk for gastrointestinal and cardiovascular complications associated with the use of nonsteroidal anti-inflammatory drugs in the CIS population: preliminary data of the CORONA-2 epidemiological survey. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):600–6. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-600-606

9. Capone M, Tacconelli S, Sciulli M, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther. 2007 Aug;322(2): 453-60. Epub 2007 May 1.

10. McGettigan P, Henry D. Use of Non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle- and high- income countries. PLoS Med. 2013;10(2):e1001388. doi: 10.1371/journal.pmed.1001388. Epub 2013 Feb 12.

11. Runkel R, Chaplin M, Boost G, et al. Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci. 1972 May;61(5):703-8.

12. Aeidler H. Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis. Arzneimittelforschung. 1975 Feb;25(2A):315-8.

13. Bowers D, Dyer H, Fosdick W, et al. Naproxen in rheumatoid arthritis. A controlled trial. Ann Intern Med. 1975 Oct;83(4):470-5.

14. Clarke A. A Double-blind comparison of naproxen against indometacin in osteoarthrosis. Arzneimittelforschung. 1975 Feb;25(2A):302-4.

15. Castles J, Moore T, Vaughan J, et al. Multicenter comparison of naproxen and indomethacin in rheumatoid arthritis. Arch Intern Med. 1978 Mar;138(3):362-6.

16. Blechman W, Willkens R, Boncaldo G, et al. Naproxen in osteoarthrosis. Doubleblind crossover trial. Ann Rheum Dis. 1978 Feb;37(1):80-4.

17. Melton JW 3rd, Lussier A, Ward JR, et al. Naproxen vs. aspirin in osteoarthritis of the hip and knee. J Rheumatol. 1978 Fall;5(3):338-46.

18. Martinez-Lavin M, Holman K, Smyth C, Vaughan J. A comparison of naproxen, indomethacin and aspirin in osteoarthritis. J Rheumatol. 1980 Sep-Oct;7(5):711-6.

19. Bjö rkenheim J, Helland J, Peltonen J. A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knee. J Int Med Res. 1985;13(5):263-9.

20. Dunn T, Clark V, Jones G. Preoperative oral naproxen for pain relief after day-case laparoscopic sterilization. Br J Anaesth. 1995 Jul;75(1):12-4.

21. Comfort V, Code W, Rooney M, Yip R. Naproxen premedication reduces postoperative tubal ligation pain. Can J Anaesth. 1992 Apr;39(4):349-52.

22. Code W, Yip R, Rooney M, et al. Preoperative naproxen sodium reduces postoperative pain following arthroscopic knee surgery. Can J Anaesth. 1994 Feb;41(2):98-101.

23. Malmstrom K, Kotey P, Coughlin H, Desjardins P. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin J Pain. 2004 May-Jun;20(3):147-55.

24. Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004234. doi: 10.1002/14651858.CD004234.pub3.

25. Simmons R, Owen S, Abbott C, et al. Naproxen sodium and paracetamol/dextropropoxyphene in sports injuries – a multicentre comparative study. Br J Sports Med. 1982 Jun;16(2):91-5.

26. Fathi M, Zare MA, Bahmani HR, Zehtabchi S. Comparison of oral oxycodone and naproxen in soft tissue injury pain control: a double-blind randomized clinical trial. Am J Emerg Med. 2015 Sep;33(9):1205-8. doi: 10.1016/j.ajem.2015.05.021. Epub 2015 May 29.

27. Friedman BW, Dym AA, Davitt M, et al. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. JAMA. 2015 Oct 20;314(15):1572-80. doi: 10.1001/jama.2015.13043.

28. Sturge RA, Scott JT, Hamilton EB, et al. Multicentre trial of naproxen and phenylbutazone in acute gout. Ann Rheum Dis. 1977 Feb;36(1):80-2.

29. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin. 1991;12(7):423-9.

30. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008 May 31;371(9627):1854-60. doi: 10.1016/S0140

31. Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014 Nov;53(11):1920-6. doi: 10.1093/rheumatology/keu157. Epub 2014 Apr 23.

32. Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. Epub 2006 Dec 1.

33. Singh G, Fort J, Goldstein J, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006 Mar;119(3):255-66.

34. Bombardier C, Laine L, Reicin A, et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528

35. Farkouh M, Kirshner H, Harrington R, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004 Aug 21-27;364(9435):675-84.

36. Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010 Feb;69(2):374-9. doi: 10.1136/ard.2009.107805. Epub 2009 Apr 12.

37. Song G, Seo Y, Kim J, et al. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. J Rheumatol. 2016 Jan 14. [Epub ahead of print]

38. Kroon FP, van der Burg LR, Ramiro S, et al. Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. J Rheumatol. 2016 Feb 1. pii: jrheum.150721. [Epub ahead of print]

39. Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014 Jan;73(1):101-7. doi: 10.1136/annrheumdis-2012-203201. Epub 2013 May 21.

40. Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract. 2002 May 22;3:10.

41. Van Hecken A, Schwartz J, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.

42. Hinz B, Cheremina O, Besz D, et al. Impact of naproxen sodium at over-thecounter doses on cyclooxygenase isoforms in human volunteers. Int J Clin Pharmacol Ther. 2008 Apr;46(4):180-6.

43. Schiff M, Hochberg M, Oldenhof J, Brune K. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin. 2009 Oct;25(10):2471-7. doi: 10.1185/030079 90903185706.

44. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086.

45. Varas-Lorenzo С, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):559-70.

46. Ray W, Varas-Lorenzo C, Chung C, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES. 108.805689. Epub 2009 May 5.

47. Gislason G, Rasmussen J, Abildstrom S, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009 Jan 26;169(2): 141-9. doi: 10.1001/archinternmed.2008.525.

48. Roumie C, Choma N, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular eventsstroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. doi: 10.1002/pds.1820.

49. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9. Epub 2014 Dec 17.

50. Antman E, Bennett J, Daugherty A, et al. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation. 2007 Mar 27; 115(12):1634-42. Epub 2007 Feb 26.

51. Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal antiinflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May;70(5):818-22. doi: 10.1136/ard.2010. 128660. Epub 2010 Sep 10.

52. Henry D, Lim L, Garcia Rodriguez L, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996 Jun 22; 312(7046):1563-6.

53. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000.

54. Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAIDinduced mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S5. doi: 10.1186/ar4177. Epub 2013 Jul 24.

55. Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015 Jan 22;7:31-41. doi: 10.2147/DHPS.S71976.eCollection 2015.

56. Goldstein J, Hochberg M, Fort J, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010 Aug;32(3):401-13. doi: 10.1111/j.1365-2036.2010.04378.x. Epub 2010 May 22.

57. Sostek M, Fort J, Estborn L, et al. Longterm safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin. 2011 Apr;27(4):847-54. doi: 10.1185/03007995.2011. 555756. Epub 2011 Feb 14.

58. Chang CC, Chiou CS, Lin HL, et al. Increased Risk of Acute Pancreatitis in Patients with Rheumatoid Arthritis: A Population-Based Cohort Study. PLoS One. 2015 Aug 11;10(8):e0135187. doi: 10.1371/journal.pone.0135187. eCollection 2015.

59. Sorensen HT, Jacobsen J, Norgaard M, et al. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment Pharmacol Ther. 2006 Jul 1;24(1):111-6.

60. Камчатнов ПР, Умарова ХЯ, Чугунов АВ. Боль в спине: проблемы выбора адекватной терапии. Consilium medicum. Неврология и ревматология (Прил). 2015;(2):22-6. [Kamchatnov PR, Umarova KhYa, Chugunov AV. Back pain: the problem of choice of adequate therapy. Consilium medicum. Neurology and rheumatology (Suppl). 2015;(2):22-6. (In Russ.)].


Для цитирования:


Каратеев А.Е. Напроксен: универсальный анальгет и к с минимальным риском кардиоваскулярных осложнений. Современная ревматология. 2016;10(2):70-77. https://doi.org/10.14412/1996-7012-2016-2-70-77

For citation:


Karateev A.E. Naproxen: A universal analgesic with a minimal risk of cardiovascular events. Modern Rheumatology Journal. 2016;10(2):70-77. (In Russ.) https://doi.org/10.14412/1996-7012-2016-2-70-77

Просмотров: 664


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)